AC Immune (NASDAQ:ACIU – Free Report) – Stock analysts at HC Wainwright issued their FY2026 earnings estimates for AC Immune in a report released on Thursday, November 5th. HC Wainwright analyst A. Ghosh forecasts that the company will earn ($0.54) per share for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for AC Immune’s Q4 2026 earnings at ($0.23) EPS, FY2027 earnings at $0.43 EPS, FY2028 earnings at $1.15 EPS, FY2029 earnings at $1.65 EPS and FY2030 earnings at $1.73 EPS.
AC Immune (NASDAQ:ACIU – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $3.88 million for the quarter, compared to analyst estimates of $1.62 million. AC Immune had a negative net margin of 181.38% and a negative return on equity of 105.25%.
Other equities research analysts have also recently issued reports about the stock. Weiss Ratings upgraded shares of AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, November 3rd. Zacks Research downgraded shares of AC Immune from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 28th. Finally, BTIG Research restated a “buy” rating and set a $8.00 price target on shares of AC Immune in a research report on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, AC Immune has a consensus rating of “Moderate Buy” and an average target price of $7.50.
Get Our Latest Stock Report on ACIU
AC Immune Stock Performance
Shares of ACIU stock opened at $2.29 on Monday. AC Immune has a fifty-two week low of $2.02 and a fifty-two week high of $3.90. The stock’s fifty day moving average is $2.53 and its two-hundred day moving average is $2.69.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership grew its holdings in shares of AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after purchasing an additional 30,035 shares during the period. Dimensional Fund Advisors LP raised its stake in AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after purchasing an additional 176,701 shares during the period. Finally, AXQ Capital LP purchased a new position in AC Immune during the second quarter worth about $25,000. Institutional investors and hedge funds own 51.36% of the company’s stock.
AC Immune Company Profile
AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau. The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.
Read More
- Five stocks we like better than AC Immune
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.
